We found that increased CDC20 (red) was observed in bladder cancer, brain and CNS cancer, cervical cancer, colorectal cancer, esophageal cancer gastric cancer, head and neck cancer, liver cancer, lung cancer, lymphoma, ovarian cancer, pancreatic cancer, sarcoma, and especially breast cancer, whereas, decreased level of CDC20 (blue) was observed in leukemia and myeloma. This evidence concerns the gene CDC20 and plasma cell myeloma.